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A 47-year-old man was admitted to explore hypertension.
The patient had a history of uncomplicated type I diabetes
(creatinine 80 mmol/l, with negative proteinuria 5 months
before). He was treated with hydrochlorothiazide–
irbesartan (12.5 mg/150 mg daily) and had no medications
known to increase serum phosphate. Physical examination
was normal. Blood pressure was 140/80 mm Hg. He
presented severe hyperphosphatemia (HP) at 10.2 mmol/l
measured by colorimetric assays using the molybdic
reagent. Other laboratory findings are summarized in
Table 1.
The bone marrow aspirate revealed a 29% infiltrates of
dysplastic plasmocytes. No osteolytic lesions were found on
skeletal X-rays. Assays for vitamin D metabolites and PTH
were normal. Multiple myeloma was diagnosed.
Postrenal obstruction was ruled out by ultrasound and
volume repletion resulted in a fall of creatinine level to
88 mmol/l. Pamidronate 90 mg was given and 40 mg/day of
intravenous dexamethasone for 4 days. Phosphate levels and
immunoglobulin G spike decreased significantly to 1 mmol/l
and 4.5 g/dl, respectively. The patient was transferred to the
Hematology department.
What is the cause for this patient’s hyperphosphatemia?
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Table 1 | Patient’s laboratory findings
Parameters Patient values Normal values
Plasma level of
Sodium (mmol/l) 130 135–145
Potassium (mmol/l) 5 3.6–5
Bicarbonates (mmol/l) 24 22–29
Magnesium (mmol/l) 0.9 0.7–0.99
Calcium (mmol/l) 10.6 mg/dl 2.68 2.10–2.65
Phosphate (mmol/l) 10.2 0.80–1.40
Uric acid (mmol/l) 369 200–420
Total protein (g/dl) 12.6 6.7–8.2
Albumin (g/dl) 3.5 3.7–5.0
Protein immunoelectrophoresis 6.7 g/dl monoclonal IgG k band
Creatinine (mmol/l) 145mmol/l 63–106
Creatinine clearance (ml/min/1.73m2) 60
Hemoglobin (g/dl) 9.6 13.0–17.0
Leukocyte count (/mm3) 7100 4000–10 000
Platelet count (/mm3) 130 000 150 000–400 000
Erythrocyte sedimentation rate (mm/h) 110 o5
Bilirubin (mmol/l) 4 2–17
Total cholesterol (mmol/l) 5.5 4.10–6.10
Triglycerides (mmol/l) 0.90 0.33–1.50
25 hydroxy vitamin D (nmol/l) 37 23–113
Parathormone (pg/ml) 84.4 12–65
Proteinuria (g/24 h) 1.5 g with k light chains o0.15
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The Diagnosis | Multiple myeloma-associated with
spurious hyperphosphatemia
DISCUSSION
Our patient had no clinical manifestations of HP, and the
serum calcium level was not decreased, as would have been
expected with the observed serum phosphate level. Renal
function was mildly altered and parathormone level
remained within normal range, excluding advanced renal
failure and hypoparathyroidism as causes of HP. Acute tumor
lysis syndrome is rarely and only observed in multiple
myeloma-treated patients. In our case, HP was seen before
treatment. Furthermore, serum uric acid, potassium, and
LDH levels—biological findings of this syndrome—were
within normal values, and ruled out this hypothesis.
We then concluded that the observed serum phosphorus
was spuriously elevated. Furthermore, when samples have
been deproteinated before analysis, serum phosphorus level
decreased from 10.2 to 1.7 mmol/l. Indeed, major fluctua-
tions in serum phosphate levels were seen, induced by the
changes in globulin and paraprotein levels that occurred
during therapy. Despite the fact that it is not currently
admitted, this observation of spurious HP in patients with
multiple myeloma may not be uncommon.
Elevated globulin fraction of the serum proteins is
responsible for spurious elevations of inorganic phosphorus
(iP) when measured by colorimetric assays before the
removal of serum proteins.1 This pseudoHP resulted from
an increase in optical density because of interference between
monoclonal immunoglobulin and the molybdic reagent used
to determine the presence of phosphate in serum. Reduction
of a phosphomolybdate compound has been the standard
colorimetric method used for the clinical determination of
serum iP since first described by Fiske and Subbarow2 in
1925. Methodological advances continued to require that
samples been deproteinated before analysis.3 The method is a
modification of phosphomolybdate colorimetry in which a
precise volume of serum-containing iP reacts with ammo-
nium molybdate in an acidic solution to form phosphomo-
lybdate. The light absorbance is then measured and is directly
proportional to the concentration of iP in the sample.
However, with the advent of discrete multiple analyzers,
excellent correlation with standard reference methods were
achieved without the need for sample deproteination.4 Many
of the currently simplified commercial kits for phosphorus
measurement used with automatic systems employ untreated
(undialyzed and diluted) serum and are, therefore, subject to
this error. However, Adler et al.5 have shown that hyperglo-
bulinemia is not invariably associated with HP, and that
increased phosphate levels appear to be determined by both
the concentration and the physicochemical characteristics of
the globulin. Indeed, almost all the cases of false HP found in
the English medical literature were associated with an
abnormal immunoglobulin G.
Spurious elevation of the serum iP concentration has also
been reported in specimens that have undergone prolonged
refrigeration or standing at room temperature, the presence
of sodium heparin in the sample, gross hemolysis (due to
release of iP from red blood cells), use of glassware
contaminated with detergents, and the presence of hyperli-
pidemia and hyperbilirubinemia. None of these other causes
appeared to be present in our patient.
In summary, our observation may have the following
clinical implications:
(1) HP associated with normal serum calcium and kidney
function may be spurious. It should alert the physician to
the possible presence of a dysglobulinemic syndrome
thus limiting unnecessary and costly investigations.
(2) Oral phosphate-binding medication should be avoided
until physicians have ascertained that the serum
inorganic phosphate level was measured in a protein-
free specimen. Indeed, aggressive therapy could lead to
true hypophosphatemia, with its clinical consequences.
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